Table 2. Univariate analysis for overall survival in patients with ⩾10 CLM (original data set).

Variables	3-year OS (%)	5-year OS (%)	MS (months)	P
Patient
Sex
Female	46	32	34	0.22
Male	56	29	40
Age (years)
<60	58	36	46	0.001
⩾60	44	21	35
Primary tumour
Location
Colon	53	31	38	0.35
Rectum	48	25	34
Stage T
T0–T2	63	26	54	0.16
T3–T4	50	29	36
Lymph node
N0	57	35	44	0.44
N+	51	27	37
CLM characteristics
Maximum tumour size
<40 mm	60	34	42	0.005
⩾40 mm	43	26	32
CEA
<100 ng ml−1	56	29	42	0.02
⩾100 ng ml−1	37	16	32
CLM distribution
Unilobar	53	30	38	0.67
Bilobar	43	43	34
Initial resectability
Unresectable	51	30	37	0.98
Resectable	52	30	37
CLM occurrence
Metachronous	48	36	34	0.22
Synchronous	53	30	38
Extrahep. disease
N	52	31	37	0.09
Y	47	22	34
Management
Preop. MRI
N	44	27	33	0.0009
Y	66	38	47
Preop. chemotherapy
N	43	27	31	0.01
Y	57	31	39
Preop. targeted therapy
N	51	23	36	0.12
Y	61	41	42
Response to preop. chemotherapy
N	54	28	38	0.42
Y	66	53	69
Portal vein embolisation
N	49	35	36	0.81
Y	56	27	40
Adjuvant chemotherapy
N	48	30	34	0.08
Y	55	31	40
Postop. targeted therapy
N	54	34	40	0.97
Y	58	27	42
Quality of resection
R2/no resection	29	5	27	<0.0001
R0/R1	61	39	49

Abbreviations: CEA=carcinoembryonic antigen; CLM= colorectal liver metastases; Extrahep.=extrahepatic; MRI=magnetic resonance imaging; MS=median survival; OS=overall survival; postop.=postoperative; preop.=preoperative.